Your browser doesn't support javascript.
The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination.
Gurney, Jason K; Millar, Elinor; Dunn, Alex; Pirie, Ruth; Mako, Michelle; Manderson, John; Hardie, Claire; Jackson, Chris G C A; North, Richard; Ruka, Myra; Scott, Nina; Sarfati, Diana.
  • Gurney JK; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Millar E; Department of Public Health, University of Otago, Mein St, Wellington, New Zealand.
  • Dunn A; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Pirie R; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Mako M; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Manderson J; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Hardie C; Te Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
  • Jackson CGCA; Midcentral District Health Board, Ruahine Street, Palmerston North, New Zealand.
  • North R; Department of Medicine, University of Otago, Great King St, Dunedin, New Zealand.
  • Ruka M; Bay of Plenty District Health Board, Cameron Rd, Tauranga, New Zealand.
  • Scott N; Waikato District Health Board, Pembroke Street, Hamilton, New Zealand.
  • Sarfati D; Waikato District Health Board, Pembroke Street, Hamilton, New Zealand.
Lancet Reg Health West Pac ; 10: 100127, 2021 May.
Article in English | MEDLINE | ID: covidwho-1144860
ABSTRACT

BACKGROUND:

The COVID-19 pandemic has disrupted cancer services globally. New Zealand has pursued an elimination strategy to COVID-19, reducing (but not eliminating) this disruption. Early in the pandemic, our national Cancer Control Agency (Te Aho o Te Kahu) began monitoring and reporting on service access to inform national and regional decision-making. In this manuscript we use high-quality, national-level data to describe changes in cancer registrations, diagnosis and treatment over the course of New Zealand's response to COVID-19.

METHODS:

Data were sourced (2018-2020) from national collections, including cancer registrations, inpatient hospitalisations and outpatient events. Cancer registrations, diagnostic testing (gastrointestinal endoscopy), surgery (colorectal, lung and prostate surgeries), medical oncology access (first specialist appointments [FSAs] and intravenous chemotherapy attendances) and radiation oncology access (FSAs and megavoltage attendances) were extracted. Descriptive analyses of count data were performed, stratified by ethnicity (Indigenous Maori, Pacific Island, non-Maori/non-Pacific).

FINDINGS:

Compared to 2018-2019, there was a 40% decline in cancer registrations during New Zealand's national shutdown in March-April 2020, increasing back to pre-shutdown levels over subsequent months. While there was a sharp decline in endoscopies, pre-shutdown volumes were achieved again by August. The impact on cancer surgery and medical oncology has been minimal, but there has been an 8% year-to-date decrease in radiation therapy attendances. With the exception of lung cancer, there is no evidence that existing inequities in service access between ethnic groups have been exacerbated by COVID-19.

INTERPRETATION:

The impact of COVID-19 on cancer care in New Zealand has been largely mitigated. The New Zealand experience may provide other agencies or organisations with a sense of the impact of the COVID-19 pandemic on cancer services within a country that has actively pursued elimination of COVID-19.

FUNDING:

Data were provided by New Zealand's Ministry of Health, and analyses completed by Te Aho o Te Kahu staff.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Lancet Reg Health West Pac Year: 2021 Document Type: Article Affiliation country: J.lanwpc.2021.100127

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Lancet Reg Health West Pac Year: 2021 Document Type: Article Affiliation country: J.lanwpc.2021.100127